

AMENDMENTS IN THE CLAIMS

Please amend claims 1, 3 and 6, and cancel claim 5 without disclaiming its subject matter, to read as follows:

1 1. (Currently Amended) A method for controlling chronic inflammation in an individual
2 having Metabolic Syndrome, comprising:

3 administering to said individual an effective dosage of a pharmaceutical composition
4 selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate
5 Subfraction, and a combination thereof.

1 2. (Original) The method of claim 1, wherein the chronic inflammation is evidenced by
2 at least one of elevated C-Reactive Protein and elevated serum fibrinogen.

1 3. (Currently amended) The method of claim 1, wherein the chronic inflammation is
2 evidenced by at least one of elevated platelet count and elevated platelet activity ~~due to the~~
3 ~~chronic inflammation.~~

1 4. (Original) The method of claim 1, wherein the individual has at least one condition
2 selected from the group consisting of hypertension, hypercholesterolemia, hypertriglyceridemia,
3 and obesity.

1 5. (Canceled)

1 6. (Currently Amended) The method of ~~claim 5~~ claim 1, wherein ~~the component of the~~
2 ~~Metabolic syndrome is the individual has at least one condition~~ selected from the group
3 consisting of obesity, insulin resistance, hypertension, dyslipidemia, impaired glucose tolerance,
4 accompanied by increased acute phase proteins including C-Reactive Protein and fibrinogen.

1 7. (Original) The method of claim 1, wherein said individual has diabetes mellitus,
2 coronary artery disease or cancer.

1 8. (Withdrawn) A method for controlling elevated blood glucose level in an individual
2 with inflammation-related metabolic disturbances, comprising:

3 administering to said individual an effective dosage of a composition selected from the
4 group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 9. (Withdrawn) The method of claim 8, wherein the individual has at least one
2 component of the Metabolic Syndrome.

1 10. (Withdrawn) A method for preventing chronic inflammation due to the presence of
2 or potential exposure to a pathogen, environmental particulates, or environmental toxins, said
3 method comprising: administering to said individual an effective dosage of a pharmaceutical
4 composition selected from the group consisting of YG-Product, YGG-Product, Purified
5 Leukocyte Dialysate Subfraction, and a combination thereof.

1 11. (Withdrawn) A method for mitigating a symptom in a patient, said symptom
2 characteristic of chronic inflammation, said patient presenting said symptom, said method
3 comprising administering to the patient a pharmaceutical preparation containing an effective
4 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 12. (Withdrawn) The method of claim 11, wherein said patient has at least one
2 component of the Metabolic Syndrome.

1 13. (Withdrawn) The method of claim 12, wherein said symptom is at least one selected
2 from the group consisting of elevated blood pressure, atherogenic dyslipidemia, abdominal
3 obesity, insulin resistance with or without glucose intolerance, a proinflammatory state, and a
4 prothrombotic state.

1 14. (Withdrawn) A method for mitigating a symptom in a patient, said symptom
2 characteristic of an inflammation-related metabolic disturbance, said patient presenting said
3 symptom, said method comprising administering to the patient a pharmaceutical preparation
4 containing an effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte
5 Dialysate Subfraction, or a combination thereof.

1 15. (Withdrawn) The method of claim 14, wherein said patient has at least one
2 component of the Metabolic Syndrome.

1 16. (Withdrawn) The method of claim 15, wherein said component is at least one
2 selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,
3 abdominal obesity, insulin resistance with or without glucose intolerance, a proinflammatory
4 state, and a prothrombotic state.

1 17. (Withdrawn) A method for deferring the progression of a patient from the Metabolic
2 Syndrome including Hypertension, to Diabetes Mellitus, Coronary Heart Disease, or Cancer,
3 said method comprising administering to the patient a pharmaceutical preparation containing an
4 effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate
5 Subfraction, or a combination thereof.

1 18. (Withdrawn) A method for preventing or mitigating development of inflammation-
2 related sequelae of exposure of a person to liquids or vapors containing organic solvents or
3 hydrocarbon fuels, or to environmental toxins capable of provoking chronic inflammation, said
4 method comprising:

5 (a) administering to the person a pharmaceutical preparation containing an effective
6 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
7 combination thereof;

8 (b) monitoring the person for immune function response, inflammation, and blood
9 glucose level; and

10 (c) continuing to administer to the patient said pharmaceutical preparation until the
11 person shows a normal immune function response and normal measures of inflammatory
12 parameters.